Atorvastatin helps keep the glue between blood vessel cells tight by stopping a chemical signal that makes the glue fall apart, which helps stop leaks in artery plaques.
Scientific Claim
Atorvastatin decreases phosphorylation of VE-Cadherin at tyrosine 685 in endothelial cells, reducing its internalization and enhancing endothelial barrier integrity in ApoE3*Leiden mice and human endothelial cells.
Original Statement
“Atorvastatin ... decreased VE-Cadherin(Y685)-phosphorylation in ECs. ... phosphorylation of VE-Cad (Y685) was dose-dependently decreased by atorvastatin, reaching basal levels at 5 µg/ml (p = 0.0317).”
Evidence Quality Assessment
Claim Status
overstated
Study Design Support
Design supports claim
Appropriate Language Strength
association
Can only show association/correlation
Assessment Explanation
The phosphorylation effect is shown in cells and mice, but not proven to be the dominant mechanism in human plaques. The claim implies a direct causal role in humans.
More Accurate Statement
“Atorvastatin is associated with reduced phosphorylation of VE-Cadherin at tyrosine 685 in human endothelial cells and mouse aortic segments, correlating with increased VE-Cadherin expression and improved endothelial barrier integrity.”
Gold Standard Evidence Needed
According to GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this specific claim, ordered from strongest to weakest evidence.
Randomized Controlled TrialLevel 1bWhether atorvastatin reduces VE-Cadherin-Y685 phosphorylation in human vascular endothelium in vivo.
Whether atorvastatin reduces VE-Cadherin-Y685 phosphorylation in human vascular endothelium in vivo.
What This Would Prove
Whether atorvastatin reduces VE-Cadherin-Y685 phosphorylation in human vascular endothelium in vivo.
Ideal Study Design
Double-blind RCT of 60 patients with carotid atherosclerosis, randomized to atorvastatin 40 mg/day vs. placebo for 8 weeks, with serial blood sampling for circulating endothelial microparticles and phospho-VE-Cadherin levels, and carotid biopsies in a subset.
Limitation: Endothelial biopsies are invasive and not feasible at scale.
Prospective Cohort StudyLevel 2bWhether lower VE-Cadherin-Y685 phosphorylation correlates with plaque stability in statin-treated patients.
Whether lower VE-Cadherin-Y685 phosphorylation correlates with plaque stability in statin-treated patients.
What This Would Prove
Whether lower VE-Cadherin-Y685 phosphorylation correlates with plaque stability in statin-treated patients.
Ideal Study Design
Prospective cohort of 200 patients with carotid plaques, measuring phospho-VE-Cadherin in plasma microparticles and plaque tissue (via immunohistochemistry) at baseline and 12 months, correlating with hemorrhage progression on MRI.
Limitation: Cannot prove causality; phosphorylation may be a consequence, not cause, of stability.
Animal StudyLevel 4In EvidenceWhether VE-Cadherin-Y685 phosphorylation is necessary for atorvastatin’s barrier-stabilizing effect.
Whether VE-Cadherin-Y685 phosphorylation is necessary for atorvastatin’s barrier-stabilizing effect.
What This Would Prove
Whether VE-Cadherin-Y685 phosphorylation is necessary for atorvastatin’s barrier-stabilizing effect.
Ideal Study Design
ApoE3*Leiden mice with vein grafts treated with atorvastatin vs. vehicle, using endothelial-specific VE-Cadherin-Y685F knock-in mice to prevent phosphorylation, measuring hemorrhage and pericyte coverage.
Limitation: Genetic manipulation may have off-target effects.
In Vitro StudyLevel 5In EvidenceWhether atorvastatin directly inhibits Src-mediated VE-Cadherin-Y685 phosphorylation in human endothelial cells.
Whether atorvastatin directly inhibits Src-mediated VE-Cadherin-Y685 phosphorylation in human endothelial cells.
What This Would Prove
Whether atorvastatin directly inhibits Src-mediated VE-Cadherin-Y685 phosphorylation in human endothelial cells.
Ideal Study Design
HUVECs treated with atorvastatin (0.5–5 µg/ml) and PMA, with or without Src inhibitor (PP2), measuring pY685-VE-Cadherin via Western blot and barrier function via transendothelial electrical resistance.
Limitation: Lacks physiological shear stress and inflammatory milieu.
Cross-Sectional StudyLevel 3Whether statin use correlates with lower VE-Cadherin-Y685 phosphorylation in human atherosclerotic plaques.
Whether statin use correlates with lower VE-Cadherin-Y685 phosphorylation in human atherosclerotic plaques.
What This Would Prove
Whether statin use correlates with lower VE-Cadherin-Y685 phosphorylation in human atherosclerotic plaques.
Ideal Study Design
Analysis of 80 human carotid endarterectomy specimens, comparing phospho-VE-Cadherin (Y685) immunostaining intensity between statin-treated and untreated patients, matched for plaque stage and LDL.
Limitation: Cannot determine if phosphorylation changes preceded or resulted from statin use.
Evidence from Studies
Supporting (1)
Atorvastatin pleiotropically decreases intraplaque angiogenesis and intraplaque haemorrhage by inhibiting ANGPT2 release and VE-Cadherin internalization
Atorvastatin helps keep the lining of blood vessels tight by stopping a specific chemical change in a protein called VE-Cadherin, which keeps the protein from being pulled inside the cells — making the vessel walls stronger and less leaky.